TuHURA Biosciences wins new US patent covering VISTA inhibitor TBS — 2025

Tuhura Biosciences received a new U.S. patent covering its VISTA-inhibiting antibody TBS-2025. Protection expands to antibody fragments, framework or Fc modifications, bispecific or multi-specific formats across human antibody classes. Claims also cover use as monotherapy or in combination regimens, including with PD-1 inhibitors. Method-of-use coverage extends beyond oncology into autoimmune disease and infection. Patent term runs to Feb. 18, 2042, before any adjustments or extensions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via (Ref. ID: LA70296) on October 13, 2026, and is solely responsible for the information contained therein. (C)